← All Amneal Pharmaceuticals, INC filings

Amneal Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
AMRX
Amneal Pharmaceuticals, INC
DEF: Amneal Pharmaceuticals Reports Strong 2025 Growth
Amneal Pharmaceuticals, Inc. reported robust financial and operational performance in 2025, driven by new product launches, double-digit revenue growth in key segments, and significant debt refinancing.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
DEFA14A: Amneal Pharmaceuticals Files Definitive Additional Proxy Soliciting Materials
Amneal Pharmaceuticals has filed definitive additional proxy soliciting materials with the SEC.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
DEF: Amneal Pharmaceuticals Sets Date for 2025 Annual Meeting, Outlines Key Proposals
Amneal Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on May 6, 2025, to vote on director elections, executive compensation, say-on-pay frequency, and auditor ratification.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
DEFA14A: Amneal Pharmaceuticals Files Definitive Proxy Statement
Amneal Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
AMRX
Amneal Pharmaceuticals, INC
DEF 14A: Amneal Pharmaceuticals Seeks Stockholder Approval for Executive Pay and Auditor Appointment at 2024 Annual Meeting
Amneal Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 2, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.